✦ LIBER ✦

Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)

✍ Scribed by Andrew S. Roberts; Michael J. Campa; Elizabeth B. Gottlin; Chen Jiang; Kouros Owzar; Hedy L. Kindler; Alan P. Venook; Richard M. Goldberg; Eileen M. O'Reilly; Edward F. Patz Jr

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 352 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26270

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 trial of gemcitabine, 5-fluoro

A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003

✍ Harvey J. Mamon; Donna Niedzwiecki; Donna Hollis; Benjamin R. Tan; Robert J. May 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 301 KB 👁 1 views

Molecular predictors of outcome in a pha

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer : National Cancer Institute of Canada Clinical Trials Group Study PA.3

✍ Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Su 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 2 views

Final survival and safety results from a

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

✍ David R. Spigel; Ming Lin; Vincent O'Neill; John D. Hainsworth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

## Abstract ## BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth factor receptor (EGFR) with a proven survival advantage for patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) who have failed a prior chemotherapy. This phase 3b, mult